Redefining Cancer Metabolism: Strategic Disruption of Lac...
2025-10-19
This thought-leadership article explores the latest frontier in cancer metabolism research: targeting monocarboxylate transporter 1 (MCT1) and mitochondrial pyruvate import using the dual-action inhibitor 7ACC2. Integrating new mechanistic insights—including the interplay between lactate flux, immunometabolic rewiring, and the tumor microenvironment—the article provides strategic guidance for translational researchers seeking to exploit metabolic vulnerabilities and reshape anti-tumor immunity. Going beyond conventional product summaries, it distills evidence from recent literature and positions 7ACC2 as a pivotal tool for next-generation oncology research.